Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xinbin Guo has a total of 72 co-authors. Here are the top co-authors by number of shared publications:

  • Xin Deng

    The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    10 shared publications
  • Sheng Guan

    First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    9 shared publications
  • Sheng Guan

    The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    4 shared publications
  • Yajing Ma

    Department of Neurointervention, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    3 shared publications
  • Zhen Chen

    Department of Neurointerventional radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

    3 shared publications
  • Chao Liu

    Department of Neurointervention, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China; and

    2 shared publications

Latest Publications

  • Safety and efficacy of endovascular treatment in symptomatic pediatric cerebral venous sinus thrombosis

    by Jinyi Li, Chunmei Wang, Kai Liu, Xiaojie Fu, Shuo Liu, Haowen Xu, Yuan Gao, Xinbin Guo, Bo Song, Sheng Guan, et al.

  • Open Access

    Dendritic cell-derived exosomes from PDT-treated glioma cells enhance antitumor immunity as a subcellular vaccine

    by Fang Wang, Shuai Ma, Zhihui Liu, Mengzhao Feng, Dengpan Song, Mengyuan Li, Yuan An, Kaiyuan Zhang, Yan Du, Shaoshan Hu, et al.

    Glioma is a highly aggressive brain tumor with a poor prognosis. Photodynamic therapy (PDT) induces antitumor immunity, a key mechanism of its efficacy. De


  • Comparative outcomes of self-expanding stenting in symptomatic MCA-M2 versus MCA-M1 segment stenosis

    by Yazhou Jin, Yueqi Zhu, Xinbin Guo, Feng Fan, Tao Quan, Jiangang Zhang, Jinyi Li, Zhen Chen, Sheng Guan, Haowen Xu

    Background: The outcomes of self-expanding stenting for symptomatic middle cerebral artery (MCA) M2 segment stenosis remain unclear. We aimed to analyze whether the safety and efficacy of M2 and M1 segment stenting procedures differ. Methods: This multicenter retrospective cohort study analyzed data from three stroke centers involving patients who underwent self-expanding stent placement for symptomatic M1 or M2 stenosis between January 2017 and August 2024. Patients were stratified into two groups: M1 stenting (M1S) and M2 stenting (M2S). Safety outcomes included 30-day peri-procedural complications, while efficacy outcomes comprised ipsilateral stroke beyond 30 days through 6 months and in-stent restenosis (ISR) at 6 months. Propensity score matching (PSM) was used to balance baseline characteristics between groups. Results: A total of 318 patients were enrolled. Compared with the M1S group, the M2S group had a similar incidence of 30-day periprocedural complications (5.0% vs 5.4%; odds ratio (OR) 1.08, 95% confidence interval (CI) 0.24 to 4.93; P=0.917), incidence of ipsilateral stroke between 30 days and 6 months postprocedure (3.1% vs 3.9%; OR 1.27, 95% CI 0.16 to 10.40; P=0.821) and ISR rate (25.0% vs 15.8%; OR 0.56, 95% CI 0.23 to 1.35; P=0.193). After a 2:1 PSM (78 vs 39 patients), the two groups remained comparable in terms of 30-day complications, the incidence of ipsilateral stroke beyond 30 days through 6 months, and the ISR rate. Conclusion: Self-expanding stenting for symptomatic M2 stenosis is technically feasible, with a safety and efficacy profile comparable to those of M1 interventions. These preliminary findings warrant validation in randomized trials.

  • Effects of dual-functional surface design on properties of bioresorbable stent molded by 3D printing

    by Yuping Zhao, Sheng Guan, Guosheng Wang, Xin Deng, Shuo Liu, Jie Cheng, Xinbin Guo


  • Predictive value of temporal muscle thickness for prognosis in newly diagnosed IDH wild-type glioblastoma patients: evaluated for a Chinese population

    by Boya Zha, Yajing Ma, Boqun Zha, Xinbin Guo

    Objectives This study aims to investigate the prognostic value of Temporal Muscle Thickness (TMT) in Chinese patients with newly diagnosed isocitrate dehydrogenase (IDH) wild-type glioblastoma. Methods Data were retrospectively collected from patients with isocitrate dehydrogenase wild-type genotype glioblastoma, who underwent surgical treatment and concurrent chemoradiotherapy at our center between May 2019 and May 2023. Multi-model and multivariate Cox regression were used to examine factors associated with overall and progression-free survival. Subgroup analysis and sensitivity tests were performed to verify the robustness of the results. Restricted cubic spline regression was used to explore the possible nonlinear relationship between TMT and OS/PFS. Results A total of 344 patients were enrolled in this study. The main analysis showed that TMT was positively correlated with overall survival and progression-free survival. The results of multivariate Cox regression after segmentation according to the optimal cutoff value showed that age ≥ 60 years (HR = 1.47, 95% CI: 1.14–1.90, p = 0.003), diabetes (HR = 1.95, 95% CI: 1.26–3.04, p = 0.003) were the risk factors for death. However, TMT ≥ 8.425 mm (HR = 0.45, 95% CI: 0.36–0.57, p < 0.001), Karnofsky ≥ 70 (HR = 0.76, 95% CI: 0.59–0.97, p < 0.031) were associated with a lower risk of death. Age ≥ 60 years (HR = 1.33, 95% CI: 1.03–1.71, p = 0.028) was a risk factor for recurrence, Karnofsky ≥ 70 (HR = 0.76, 95% CI: 0.59–0.97, p = 0.027), TMT ≥ 8.4 mm (HR = 0.64, 95% CI: 0.50–0.80, p < 0.001), and combination of targeted therapy (HR = 0.65, 95% CI: 0.47–0.90, p = 0.01) reduced recurrence risk. Conclusion TMT is an independent predictor of OS and PFS in IDH wild-type GBM patients and can be used to predict prognosis in clinical practice. Key Points Question Performance status of glioblastoma patients is crucial for treatment decision-making and prognosis assessment; however, there is currently no objective evaluation metric for the Chinese population. Findings Temporal muscle thickness at initial diagnosis is positively correlated with overall survival and progression-free survival in Chinese patients with newly diagnosed IDH wild-type glioblastoma. Clinical relevance Temporal muscle thickness at initial diagnosis is an independent, objective prognostic factor for newly diagnosed IDH wild-type glioblastoma patients in China. It contributes to the formulation of individualized treatment plans and serves as a stratification factor in clinical trials.


  • Value of difference in diameters between Pipeline embolization device and parent artery in assessing aneurysm outcome

    by Yajing Ma, Hang Zhang, Chao Liu, Xin Deng, Yongjie Yuan, Sheng Guan, Xinbin Guo

    OBJECTIVE: In vitro trials have demonstrated that oversized stents are associated with reduced metal coverage and increased porosity. However, the relationship between stent selection and aneurysm outcome is inconclusive, and determination of this was the authors’ purpose in conducting this study. METHODS: This was a single-center retrospective study. Patients who underwent Pipeline embolization device treatment at the authors’ center between January 1, 2018, and June 15, 2023, were enrolled. The authors constructed multiple logistic regression models and restricted cubic spline plots to examine the effect of the difference in diameters between the stent and parent artery (Dd) on aneurysm outcome. The authors also performed stratified analyses. Then, Dd was included in the logistic regression analysis as a categorical variable. The cutoff value for Dd was determined according to the principle of the maximum Youden’s index. RESULTS: In total, 302 patients were included in this study. The median Dd was 0.52 mm. With a median follow-up time of 7 months, the aneurysm occlusion rate was 80.1%. The restricted cubic spline plots showed a decreasing aneurysm occlusion rate as Dd increased. After stratification by age and adjunctive embolization, the restricted cubic splines aligned with the results of the main analysis. Compared with the group with a smaller Dd (Dd < 0.3625 mm), the group with a larger Dd showed an OR of 0.439 (p = 0.026). Additionally, patients with diabetes mellitus (OR 0.306, p = 0.018), age ≥ 65 years (OR 0.968, p = 0.03), aneurysm incorporation with a branch (OR 0.253, p < 0.001), and aneurysm neck ≥ 4 mm (OR 0.872, p = 0.003) were independent predictors of aneurysm persistence, whereas Pipeline embolization device plus coiling (OR 4.949, p < 0.001) and smoking history (OR 5.86, p = 0.025) were predictors of aneurysm occlusion. CONCLUSIONS: The authors’ retrospective analysis demonstrated that the aneurysm occlusion rate declined when Dd increased within a certain range. The authors suggested that Dd with an interval of −0.25 to 0.5 mm may be proper in clinical practice.


  • Open Access

    HAX-1 interferes in assembly of NLRP3-ASC to block microglial pyroptosis in cerebral I/R injury

    by Xin-Bin Guo, Xin Deng, Jingjing Wang, Yuruo Qi, Wen Zhao, Sheng Guan

    Acute cerebral ischemia has a high rate of disability and death. Although timely recanalization therapy may rescue the ischemic brain tissue, cerebral ischemia-reperfusion injury has been shown to limit the therapeutic effects of vascular recanalization. Protein HAX-1 has been reported as a pro-survival protein that plays an important role in various disorders, particularly in association with the nervous system. However, the effects and mechanisms of HAX-1 in cerebral IR injury have yet to be elucidated. So, we aimed to investigate the effect of HAX-1 on microglial pyroptosis and explore its potential neuroprotective effects in ischemia-reperfusion injury. Our results show that the expression of HAX-1 decreased after cerebral IR injury, accompanied by an increase in pyroptosis pathway activation. In addition, HAX-1 could inhibit microglial pyroptosis both in vivo and in vitro and reduce the release of inflammatory mediators. The above neuroprotective effects might be partially mediated by inhibiting of interaction of NLRP3 and ASC through competitive binding, followed by the attenuation of NLRP3 inflammasome formation. In conclusion, Our findings support that HAX-1 exhibits a protective role in cerebral I/R injury, and further study on HAX-1 expression regulation will contribute to cerebral infarction therapy.


  • Open Access

    Predictors of In-Stent Stenosis Following the Implantation of Pipeline Embolization Devices for the Treatment of Aneurysms Located at or beyond the Circle of Willis in the Anterior Circulation

    by Yajing Ma, Xin Deng, Junfan Chen, Feng Fan, Kaihao Han, Sheng Guan, Xinbin Guo

    BACKGROUND AND PURPOSE: In-stent stenosis is commonly observed after stent implantation. There is no consensus on the contributing factors for in-stent stenosis, especially for aneurysms located at or beyond the circle of Willis in the anterior circulation. This study aimed to investigate the morbidity and determinants of in-stent stenosis in distal anterior circulation aneurysms following the implantation of Pipeline Embolization Devices. MATERIALS AND METHODS: Patients who underwent Pipeline Embolization Device treatment at our center between January 1, 2018, and June 15, 2023, were enrolled. Distal anterior circulation aneurysms were defined as those occurring at or beyond the circle of Willis, including anterior communicating artery aneurysms, anterior cerebral artery aneurysms, and MCA aneurysms. Baseline information, aneurysm characteristics, and follow-up data of patients were analyzed. Patients were divided into 2 groups: the in-stent stenosis group (patients with a loss of >25% of the lumen diameter of the parent artery) and the non-in-stent stenosis group. Binary logistic regression and restricted cubic spline curves were used to explore risk factors. RESULTS: We included 85 cases of 1213 patients treated with flow-diverter devices at our hospital. During an average follow-up period of 9.07 months, the complete occlusion rate was 77.64%. The overall incidence of in-stent stenosis was 36.47% (31/85), of which moderate stenosis accounted for 9.41% (8/85), and severe stenosis, 5.88% (5/85) (triglyceride-glucose index ≥ 8.95; OR = 6.883, P = .006). The difference in diameters between the stent and parent artery of ≥0.09 mm (OR = 6.534, P = .015) and 55 years of age or older (OR = 3.507, P = .036) were risk factors for in-stent stenosis. The restricted cubic spline curves indicated that the risk of in-stent stenosis increased as the difference in diameter between stent and parent artery and the triglyceride-glucose index increased. CONCLUSIONS: Compared with the on-label use of Pipeline Embolization Devices, the rate of in-stent stenosis did not obviously increase when treating distal anterior circulation aneurysms with these devices. The incidence of in-stent stenosis was 36.47% when defined as a lumen diameter loss of >25%, and 15.2% when defined as a lumen diameter loss of >50%. Stent-size selection and biochemical indicators can potentially impact the incidence of in-stent stenosis.


  • Risk factor analysis of changes in blood flow in the A1 segment of the anterior cerebral artery after flow-diverter coverage of it

    by WuLin Ma, Xin Deng, JunFan Chen, XinBin Guo

    Few studies have explored the effect of a flow-diverter device (FD) on blood flow in the A1 segment of the anterior cerebral artery (ACA), after treatment of intracranial aneurysms in the bifurcation region of the internal carotid artery (ICA). The main objective of this article is to investigate the factors that affect A1 blood flow after FD covers the A1 artery. This is a single-center, retrospective study. Data were collected retrospectively from our center, and patients whose FDs were placed for treatment from the terminal of the ICA to the M1 segment were analyzed. A total of 42 patients were included in the study. Immediate post-procedural angiography following device placement revealed decreased blood flow in the A1 of 15 (35.7%) patients and complete occlusion of the A1 segment in 11 (26.2%) patients. During an average follow-up period of 9.8 months, the A1 segment was ultimately occluded in 25 patients (59.5%) and decreased blood flow in 4 patients (9.5%). When using FD to cover the A1 artery for the treatment of intracranial aneurysms, patients with preoperative opening of the anterior communicating artery (AcomA) are more prone to occlusion or decreased blood flow of the A1 artery, compared to patients without opening.